Get the Stockscreener App
33.41
3.02%
0.98
Celldex Therapeutics Inc stock is traded at $33.41, with a volume of 1.96M.
It is up +3.02% in the last 24 hours and up +8.72% over the past month.
Celldex Therapeutics Inc is a biopharmaceutical firm focused on mast cell biology and the development of therapeutic antibodies. Its pipeline includes monoclonal and bispecific antibodies aimed at treating severe inflammatory, allergic, autoimmune, and other mast cell-mediated diseases. The company operates in a single operating and reportable segment in the business of development, manufacturing and commercialization of novel therapeutics for human health care.
See More
Previous Close:
$32.43
Open:
$32.9
24h Volume:
1.96M
Relative Volume:
1.98
Market Cap:
$2.62B
Revenue:
$1.55M
Net Income/Loss:
$-258.76M
P/E Ratio:
-8.577
EPS:
-3.8953
Net Cash Flow:
$-213.66M
1W Performance:
+4.02%
1M Performance:
+8.72%
6M Performance:
+22.52%
1Y Performance:
+62.98%
1-Day Range:
$32.26
$33.46
1-Week Range:
$31.41
$34.14
52-Week Range:
$19.52
$35.79
Celldex Therapeutics Inc Stock (CLDX) Company Profile
Name
Celldex Therapeutics Inc
Sector
Industry
Phone
908-200-7500
Address
53 FRONTAGE ROAD, HAMPTON
Compare CLDX vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CLDX
Celldex Therapeutics Inc
|
33.41 | 2.55B | 1.55M | -258.76M | -213.66M | -3.8953 |
VRTX
Vertex Pharmaceuticals Inc
|
466.79 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
612.50 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
903.75 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
286.41 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
165.81 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Celldex Therapeutics Inc Stock (CLDX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-20-26 | Upgrade | Barclays | Underweight → Overweight |
| Mar-23-26 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Oct-21-25 | Initiated | Mizuho | Outperform |
| Oct-13-25 | Initiated | Barclays | Underweight |
| Apr-28-25 | Initiated | Canaccord Genuity | Buy |
| Mar-20-25 | Initiated | Morgan Stanley | Overweight |
| Feb-13-25 | Initiated | UBS | Buy |
| Oct-07-24 | Initiated | Citigroup | Buy |
| Sep-30-24 | Initiated | Goldman | Neutral |
| Sep-27-24 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Jun-18-24 | Initiated | Stifel | Buy |
| Jun-11-24 | Initiated | Wolfe Research | Outperform |
| Dec-20-23 | Initiated | TD Cowen | Outperform |
| Nov-10-23 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Aug-22-23 | Initiated | Wells Fargo | Underweight |
| Sep-17-21 | Initiated | Jefferies | Buy |
| Sep-10-21 | Initiated | SVB Leerink | Outperform |
| Jul-22-21 | Initiated | Guggenheim | Buy |
| Feb-21-20 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-01-17 | Resumed | H.C. Wainwright | Buy |
| Nov-07-16 | Initiated | Aegis Capital | Buy |
| Mar-08-16 | Downgrade | Jefferies | Buy → Hold |
| Mar-07-16 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-07-16 | Downgrade | Leerink Partners | Outperform → Mkt Perform |
| Mar-07-16 | Downgrade | Wedbush | Outperform → Neutral |
| Mar-01-16 | Initiated | H.C. Wainwright | Buy |
| Aug-11-15 | Reiterated | Brean Capital | Buy |
| Aug-11-15 | Reiterated | Oppenheimer | Outperform |
| Aug-11-15 | Reiterated | ROTH Capital | Buy |
| Jun-02-15 | Reiterated | WBB Securities | Strong Buy |
| Nov-17-14 | Reiterated | ROTH Capital | Buy |
| Mar-04-14 | Reiterated | Oppenheimer | Outperform |
| Jul-08-13 | Reiterated | Cantor Fitzgerald | Buy |
| Mar-08-13 | Reiterated | Cantor Fitzgerald | Buy |
| Feb-26-13 | Reiterated | Oppenheimer | Outperform |
| Jan-10-13 | Reiterated | Cantor Fitzgerald | Buy |
| Oct-02-12 | Reiterated | Oppenheimer | Outperform |
| Sep-14-12 | Reiterated | Cantor Fitzgerald | Buy |
View All
Celldex Therapeutics Inc Stock (CLDX) Latest News
Celldex Therapeutics (CLDX) Stock Could Be 61% Below Fair Value After New Trial Data - Sahm
Chronic Spontaneous Urticaria Pipeline Gains Momentum: 20+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight - Barchart.com
Celldex Therapeutics Inc (CLDX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Celldex Therapeutics Inc (CLDX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Celldex Therapeutics Inc (CLDX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Celldex Therapeutics Inc (CLDX) Institutional Confidence - TradingKey
Celldex Therapeutics Inc (CLDX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Celldex Therapeutics Inc (CLDX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Celldex Therapeutics StockUBS reiterates Buy after data update - AD HOC NEWS
Celldex Therapeutics Inc (CLDX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Why Celldex Therapeutics (CLDX) Is Up 12.2% After CSU Drug Data Suggest Disease Modification Potential - Sahm
Celldex Therapeutics Inc (CLDX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Celldex Therapeutics Inc (CLDX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Analysts Offer Insights on Healthcare Companies: Celldex (CLDX) and MoonLake Immunotherapeutics (MLTX) - The Globe and Mail
Celldex Therapeutics Says Barzolvolimab Meets Primary Efficacy Endpoint In Phase 2 CSU Study - TradingView
Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology Annual Meeting - Yahoo! Finance Canada
New Celldex antibody depletes mast cells in first human test - Stock Titan
Celldex reports positive phase 1 data for CDX-622 antibody By Investing.com - Investing.com Canada
Celldex Presents Positive Phase 1 Results for CDX-622, a Novel Bispecific Antibody for Mast Cell Depletion and TSLP Inhibition at EAACI Annual Meeting - Quiver Quantitative
Celldex Presents Positive First-in-Human Results from Phase 1 Study of Novel Bispecific CDX-622 at the European Academy of Allergy and Clinical Immunology Annual Meeting - Yahoo Finance
Celldex Data At 2026 EAACI Puts Mast Cell Pipeline In Focus - Sahm
A Look At Celldex Therapeutics (CLDX) Valuation After Recent Share Price Pullback And Mixed P/B And DCF Signals - Sahm
Celldex to present barzolvolimab, CDX-622 data at EAACI congress By Investing.com - Investing.com Canada
Celldex to present mast cell targeting drug data at European congress - StreetInsider
Celldex Announces Multiple Upcoming Presentations from Leading Mast Cell Targeting Pipeline at the Upcoming 2026 European Academy of Allergy and Clinical Immunology Annual Congress - Yahoo Finance
UBS Adjusts Price Target on Celldex Therapeutics to $45 From $38, Maintains Buy Rating - marketscreener.com
CLDX Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Celldex closes $345 million stock offering - Investing.com
CLDX News | CELLDEX THERAPEUTICS INC (NASDAQ:CLDX) - ChartMill
Wall Street analysts see a 76.42% upside in Celldex (CLDX): Can the stock really move this high? - MSN
Celldex Therapeutics | SCHEDULE 13G/A: Others - Moomoo
Celldex Therapeutics (CLDX) Edges Lower Amid Consolidation Near Key SupportReversal Trade - newsline.com
CLDX Q1 2026 Earnings: Celldex Reports EPS Miss Amid Early-Stage Pipeline ProgressConsensus Forecast Report - newsline.com
ELVN Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
A Quick Look at Today's Ratings for Celldex Therapeutics(CLDX.US), With a Forecast Between $38 to $67 - Moomoo
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
Kynam Capital reports 5.84M-share (8.77%) position in Celldex (CLDX) - Stock Titan
Bellevue (CLDX) holds 1.2M shares (1.5%) — files Amendment No.1 - Stock Titan
Wall Street Analysts See a 76.42% Upside in Celldex (CLDX): Can the Stock Really Move This High? - Eastern Progress
Celldex Therapeutics stock (US15117B1035): Wells Fargo raises price target to $54 - AD HOC NEWS
Celldex Therapeutics Inc (NASDAQ:CLDX) Shows Strong Technical Breakout Setup - ChartMill
CLDX SEC FilingsCelldex Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Wells Fargo raises Celldex Therapeutics price target on PN data By Investing.com - Investing.com UK
Assessing Celldex Therapeutics (CLDX) Valuation After Recent Share Price Pullback And Mixed Signals - Yahoo Finance
State Street (CLDX) reports 2.8M shares, 4.2% stake in CELLDex Therapeutics - Stock Titan
The Bull Case For Celldex Therapeutics (CLDX) Could Change Following Q1 Loss And Barzolvolimab Milestones - Sahm
LifeSci Capital Maintains Celldex Therapeutics(CLDX.US) With Buy Rating, Maintains Target Price $67 - Moomoo
RLAY Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Weighing Celldex Therapeutics (CLDX) Valuation As Price-To-Book And DCF Send Mixed Signals - Sahm
Celldex Therapeutics Inc expected to post a loss of $1.15 a shareEarnings Preview - TradingView
12 Health Care Stocks Moving In Friday's Pre-Market SessionAbsci (NASDAQ:ABSI), Amylyx Pharmaceuticals - Benzinga
Celldex Therapeutics Inc Stock (CLDX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.57%
1.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):